Business
Sernova Provides Corporate Update and Outlook for 2020
(via TheNewswire) LONDON, ONTARIO - TheNewswire - March 24, 2020 - Ser...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Provides Corporate Update and Outlook for 2020(via TheNewswire)\n \n \nLONDON, ONTARIO - TheNewswire - March 24, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, today provided a corporate update and outlook for 2020.\n\n\n \nDr. Philip Toleikis, President and CEO of Sernova Corp., remarked, \"The past year has been one of significant advancement and success for Sernova's clinical and preclinical programs. We are pleased with the progress, including increased patient enrollment and early observations from our US Phase I/II clinical trial for people with type 1 diabetes and severe hypoglycemia unawareness. Advancements have also been made with preclinical initiatives for our Cell Pouch System(TM) platform relating to the development of stem cell-derived islets toward the ultimate goal of developing an unlimited source of therapeutic cells for diabetes, factor VIII producing cells for hemophilia A and a novel treatment for people with hypothyroid disease. We also continue to evolve and make progress with our pharma and academic collaborations. Despite the current COVID-19 environment, we are encouraged with the path ahead for Sernova and what we expect to achieve in 2020 to enhance long-term shareholder value.\" \n\n\n \nThe following enumerates recent progress and achievements for Sernova's pipeline by therapeutic indication and area of interest.\n\n\n \nDiabetes\n\n\n \nWe are currently conducting a US Phase I/II clinical trial in type 1 diabetic patients with severe hypoglycemia unawareness - entitled \"Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch(TM) for Clinical Islet Transplantation\" - at the University of Chicago (\"US Phase I/II Cell Pouch Clinical Trial\").\n\n\n \nKey requirements for a successful diabetes regenerative medicine approach have been our focus, more specifically, these include first ensuring robust survival of insulin-producing cells within our Cell Pouch and proof of insulin release into the bloodstream in subjects with no ability to produce insulin prior to Cell Pouch transplant. \n\n\n \nThe following represents significant achievements for the US Phase I/II Cell Pouch Clinical Trial:\n\n\n \n\n\n- Increased number of patients enrolled and transplanted in our clinical trial. In the most advanced patient treated ...